AB1168 CLINICAL AND SEROLOGICAL EVOLUTION OF RHEUMATIC PATIENTS INFECTED BY SARS-COV-2

Background SARS-CoV-2 infection is a public health problem due to its high contagiousness and mortality. Spectrum of symptoms ranges from no interstitial pneumonia. Patients with rheumatic disease present an increased infectious risk, especially those treated immunosuppressants or biologic therapy. Since the beginning pandemic, risk contagion development complications in these patients has been questioned. Objectives To describe hospitalization prevalence, seroconversion, under follow-up by rheumatology department tertiary hospital. Methods Observational, cross-sectional study conducted phone interview including different diagnosis rhematic diseases. Data about symptoms, hospital admission, serology ELISA (when >15 days evolution), baseline treatment, March 2020 February 2021 were collected. Results Eighty-six diseases positive COVID-19 PCR included (82.35% women) Table 1. Mean age was 49.30 years (16.16). The 48.71% received biological therapy, JAK inhibitors apremilast, median 3.11 (Q1 1,08; Q3 3,17). Secukinumab therapy most often used (24,32%), followed Tocilizumab (13,51%). 34,18% DMARDs immunosuppressors, 5.09 12,25; 11.09). frequent asthenia (72.15%), headache (66.23%) cough (59.49%). Nine (11.25%) admitted hospital, eight them (10%) for Three intensive care one died. Seroconversion occurred 53.25%. low IgG titers 2.94% IgM persisted 56.25% this group. In 6.45% result indeterminate. Diagnosis Number (%) Rheumatoid arthritis 24% Psoriasic 16% Ankylosing espondilitis Systemic erythematosus lupus 8% Juvenile idiopathic sclerosis 7% Behçet 5% Sjögren syndrome 3% Mediterranean fever Sarcoidosis 1% Granulomatosis polyangitis Mixed connective tissue Leucocitoclastic vasculitis Rhupus Rheumatic polymyalgia Dermatomyositis Cutaneous panarteritis Conclusion Hospitalization mortality rate obtained mild. more than 50% It’s important highlight that since May prevalence 25%, while September 2021, until 57,45%. This difference modification autoantibody detection technique summer 2020. Disclosure Interests None declared